Patent intelligence · US
US 9610358
Targeted pharmacological chaperones
Targeted pharmacological chaperones
Patent details — US 9610358
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 4, 2017
- Expiration
- Mar 30, 2037
- Applicant
- Marker Gene Technologies, Inc
- Claims
- 14
- CPC classes
- A61K, A61K31/445, A61K47/64, A61K47/645
Quick answer
US 9610358 (Targeted pharmacological chaperones) is held by Marker Gene Technologies, Inc. Status: granted. Granted Apr 4, 2017. Expires Mar 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Marker Gene Technologies, Inc
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/445, A61K47/64, A61K47/645
More from Marker Gene Technologies, Inc
Related pharmaceutical patents in our USPTO index.
-
US 12077601
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11885817
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11692030
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11598782
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11447500
Thienopyridine derivatives and pharmaceutical composition comprising same
granted -
US 11186873
Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
granted -
US 11078298
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11008622
Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof
granted
Frequently asked questions
What is US patent 9610358?
US 9610358 (Targeted pharmacological chaperones) is held by Marker Gene Technologies, Inc. Status: granted. Granted Apr 4, 2017. Expires Mar 30, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9610358?
Marker Gene Technologies, Inc is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 9610358 expire?
Our index shows an expiration date of Mar 30, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.